(Q43986810)

28 November 2017

title

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma (English)

1 reference

28 November 2017

main subject

phase II clinical trial

0 references

1 reference

Maria L Delioukina

1

1 reference

28 November 2017

Diane Prager

2

1 reference

28 November 2017

Mandy Parson

3

1 reference

28 November 2017

J Randolph Hecht

4

1 reference

28 November 2017

Peter Rosen

5

1 reference

28 November 2017

Lee S Rosen

6

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

28 November 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

28 November 2017

volume

94

1 reference

28 November 2017

issue

8

1 reference

28 November 2017

page(s)

2174-2179

1 reference

The current status of camptothecin analogues as antitumor agents

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

CPT-11 in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Irinotecan in the treatment of colorectal cancer: clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Phase I/II trials of WR-2721 and cis-platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

Intracolonic WR 2721 protection of the rat colon from acute radiation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

The Effect of S-2-(3-Aminopropylamino)Ethylphosphorothioic Acid (WR-2721) on Intestinal Crypt Survival I. 4 MeV X-Rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10432

21 January 2018

Identifiers

DOI

10.1002/CNCR.10432

1 reference

28 November 2017

1 reference